Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Lung cancer

Maintenance therapy and precision medicine in NSCLC

Nature Reviews Clinical Oncology volume 10, pages 549–550 (2013)Cite this article

Subjects

Two phase III trials have shown that prolonging chemotherapy duration improves outcome in patients with nonsquamous non-small-cell lung cancer. Pemetrexed versus placebo, and pemetrexed–bevacizumab versus bevacizumab was tested in patients without disease progression after pemetrexed–cisplatin treatment. Biomarker-directed chemotherapy and/or targeted therapy could further improve treatment outcomes for patients with lung cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Potentially 'druggable' lung cancer targets.

References

  1. Paz-Ares, L. et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 13, 247–255 (2012).

    Article  CAS  Google Scholar 

  2. Barlesi, F. et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.42.3749.

  3. Paz-Ares, L. G. et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.47.1102.

  4. Karnofsky, D. A., Abelmann, W. H,, Craver, L. F. & Burchenal, J. H. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma Cancer 1, 634–656 (1948).

    Article  Google Scholar 

  5. Westeel, V. et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J. Natl Cancer Inst. 97, 499–506 (2005).

    Article  CAS  Google Scholar 

  6. Scagliotti, G. V. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26, 3543–3551 (2008).

    Article  CAS  Google Scholar 

  7. Nicolson, M. C. et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J. Thorac. Oncol. 8, 930–939 (2013).

    Article  CAS  Google Scholar 

  8. Rosell, R., Bivona, T. G. & Karachaliou, N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet (in press).

  9. Dominguez, C. L. et al. Diacylglycerol kinase alpha is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov. 3, 782–797 (2013).

    Article  CAS  Google Scholar 

  10. Pullamsetti, S. S. et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene 32, 1121–1134 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors acknowledge support from La Caixa Foundation and Redes Temáticas de Investigación en Cáncer (RD12/0036/0072).

Author information

Authors and Affiliations

  1. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Carreterra del Canyet s/n, Badalona, 08916, Barcelona, Spain

    Rafael Rosell

  2. Quirón Dexeus University Hospital, Sabino Arana 5–19, 08028, Barcelona, Spain

    Niki Karachaliou

Authors
  1. Rafael Rosell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niki Karachaliou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael Rosell.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosell, R., Karachaliou, N. Maintenance therapy and precision medicine in NSCLC. Nat Rev Clin Oncol 10, 549–550 (2013). https://doi.org/10.1038/nrclinonc.2013.152

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.152

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer